EMA Restricts Rubraca’s Use Due To Concerns Over Benefit & Safety

Clovis Voluntarily Dropped Drug’s Third-Line Ovarian Cancer Indication In US

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".